U.S. Markets closed

Pfizer, NIH Mulling Study For Longer Paxlovid Course To Combat Reinfections

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • The U.S. National Institutes of Health and Pfizer Inc (NYSE: PFE) are discussing testing a longer course of COVID-19 antiviral treatment Paxlovid, required to prevent reinfections, White House Chief Medical Officer Anthony Fauci said.

  • "We're going to be planning what studies we're going to be doing relatively soon, within the next few days," to determine whether a longer course is needed, Fauci said during a White House COVID-19 briefing.

  • White house estimates that about 20,000 prescriptions of Paxlovid are being given out every day.

  • Also Read: COVID-19 Symptoms Rebound After Pfizer's COVID-19 Therapy, What Could Be The Reason?

  • Pfizer has suggested that a second five-day course of Paxlovid could treat reinfections. The FDA said there is currently no evidence to support taking a second five-day course or a 10-day course of the pills.

  • In Pfizer's clinical trial, around 2% of recipients who received the two-drug treatment saw an increase in viral load after completing the standard course, compared with around 1.5% of placebo recipients.

  • Price Action: PFE shares are up 0.07% at $50.44 during the market session on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.